The impact of end-stage kidney disease on hospitalization outcomes in patients with complete heart block: insights from united states population data.

IF 1.8 4区医学 Q3 UROLOGY & NEPHROLOGY

International Urology and Nephrology Pub Date : 2025-04-05 DOI:10.1007/s11255-025-04474-6

Nadhem Abdallah, Abdilahi Mohamoud, Mahmoud Ismayl, Ammar Aladaileh, Charles A Herzog

{"title":"The impact of end-stage kidney disease on hospitalization outcomes in patients with complete heart block: insights from united states population data.","authors":"Nadhem Abdallah, Abdilahi Mohamoud, Mahmoud Ismayl, Ammar Aladaileh, Charles A Herzog","doi":"10.1007/s11255-025-04474-6","DOIUrl":null,"url":null,"abstract":"Introduction: Patients with end stage kidney disease (ESKD) suffer higher rates of mortality, partly because of cardiac conduction abnormalities. Despite this, data on complete heart block (CHB) cases in patients with ESKD remain limited.Methods: Admissions for CHB were identified in the 2016-2019 National Inpatient Sample. In-hospital outcomes were compared between patients with and without ESKD. The primary outcome was mortality. Secondary outcomes included, Permanent Pacemaker (PPM) and Temporary Pacemaker (TPM) use, palliative care, vasopressor use, mechanical ventilation use, length of stay (LOS), and total charges. Multivariable regression models were used to adjust for confounders.Results: Among 150,265 hospitalizations with a primary diagnosis of CHB, 5,109 (3.4%) had a diagnosis of ESKD. ESKD was associated with higher odds of mortality (adjusted Odds Ration [aOR] 1.54, 95% CI 1.15-2.07), vasopressors use (aOR 1.9, 95% CI 1.25-2.88), mechanical ventilation (aOR 1.26, 95% CI 1.03-1.56), palliative care (aOR 1.41, 95% CI 1.03-1.94), TPM use (aOR 1.26, 95% CI 1.09-1.47), lower odds of PPM use (aOR 0.54, 95% CI 0.47-0.62), longer LOS (+ 1.29 days, p < 0.001) and higher charges ($123,110 vs. $87,235, p < 0.001).Conclusion: Patients with ESKD admitted for CHB had higher fatal and non-fatal adverse outcomes compared to patients without ESKD.","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Urology and Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11255-025-04474-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Patients with end stage kidney disease (ESKD) suffer higher rates of mortality, partly because of cardiac conduction abnormalities. Despite this, data on complete heart block (CHB) cases in patients with ESKD remain limited.

Methods: Admissions for CHB were identified in the 2016-2019 National Inpatient Sample. In-hospital outcomes were compared between patients with and without ESKD. The primary outcome was mortality. Secondary outcomes included, Permanent Pacemaker (PPM) and Temporary Pacemaker (TPM) use, palliative care, vasopressor use, mechanical ventilation use, length of stay (LOS), and total charges. Multivariable regression models were used to adjust for confounders.

Results: Among 150,265 hospitalizations with a primary diagnosis of CHB, 5,109 (3.4%) had a diagnosis of ESKD. ESKD was associated with higher odds of mortality (adjusted Odds Ration [aOR] 1.54, 95% CI 1.15-2.07), vasopressors use (aOR 1.9, 95% CI 1.25-2.88), mechanical ventilation (aOR 1.26, 95% CI 1.03-1.56), palliative care (aOR 1.41, 95% CI 1.03-1.94), TPM use (aOR 1.26, 95% CI 1.09-1.47), lower odds of PPM use (aOR 0.54, 95% CI 0.47-0.62), longer LOS (+ 1.29 days, p < 0.001) and higher charges ($123,110 vs. $87,235, p < 0.001).

Conclusion: Patients with ESKD admitted for CHB had higher fatal and non-fatal adverse outcomes compared to patients without ESKD.

查看原文本刊更多论文

终末期肾病对完全性心脏传导阻滞患者住院治疗结果的影响：美国人口数据的启示。

终末期肾病（ESKD）患者的死亡率较高，部分原因是心脏传导异常。尽管如此，ESKD患者完全性心脏传导阻滞（CHB）病例的数据仍然有限。方法：从2016-2019年全国住院患者样本中确定CHB入院情况。比较了ESKD患者和非ESKD患者的住院结果。主要结局是死亡率。次要结果包括永久性起搏器（PPM）和临时起搏器（TPM）的使用、姑息治疗、血管加压剂的使用、机械通气的使用、住院时间（LOS）和总费用。多变量回归模型用于校正混杂因素。结果：在150265例初步诊断为慢性乙型肝炎的住院患者中，5109例（3.4%）诊断为ESKD。ESKD与较高的死亡率（调整比值比[aOR] 1.54, 95% CI 1.15-2.07）、血管加压剂的使用（aOR 1.9, 95% CI 1.25-2.88）、机械通气（aOR 1.26, 95% CI 1.03-1.56）、姑息治疗（aOR 1.41, 95% CI 1.03-1.94）、TPM的使用（aOR 1.26, 95% CI 1.09-1.47）、较低的PPM使用几率（aOR 0.54, 95% CI 0.47-0.62）、较长的LOS（+ 1.29天，p）相关。结论：与没有ESKD的患者相比，ESKD患者因CHB入院的致命和非致命不良结局更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Urology and Nephrology 医学-泌尿学与肾脏学

CiteScore

3.40

自引率

5.00%

发文量

329

审稿时长

1.7 months

期刊介绍： International Urology and Nephrology publishes original papers on a broad range of topics in urology, nephrology and andrology. The journal integrates papers originating from clinical practice.